Aiko Medical's Secretary of the Board of Directors, Ding Lin, born in the 75s, also serves as the Chief Financial Officer. His background includes experience at Citibank and Fosun High Tech.

Rui Finance Liu Zhiying On March 24, Aike Medical Devices (Beijing) Co., Ltd. (hereinafter referred to as “Aike Medical”) was accepted for its IPO on the Sci-Tech Innovation Board, with CITIC Securities as the sponsor, and Chen Wei and Ma Xiang as the sponsoring representatives. Ernst & Young Hua Ming is the accounting firm.

According to Rui Finance, this is Aike Medical’s second attempt at an IPO. It had previously submitted its application for the Sci-Tech Innovation Board IPO on April 20, 2023, which was terminated on April 11, 2024, after undergoing one round of inquiry responses.

Aike Medical was founded in August 2017, with a registered capital of 43.0842 million yuan. It is a national high-tech enterprise at the commercialization stage, focusing on innovative medical devices in the field of neurointervention, integrating research and development, production, and commercialization, and has been recognized as a national-level specialized and innovative “little giant.”

As of the signing date of the prospectus, Aike Medical has obtained approval for ten types of Class III medical devices in China, including innovative medical device products such as the Lattice® flow-directed stent, Grism® distal occlusion intracranial thrombectomy stent, and Attractor® intracranial thrombus aspiration catheter, with products gradually approved or registered in overseas markets such as the United States and Southeast Asia. Additionally, the company has several products in clinical or preclinical research stages.

In this IPO, Aike Medical aims to raise 1.1 billion yuan, which will be used for the production construction project of neurointerventional medical devices, research and development projects for neurointerventional medical devices, marketing network construction projects, and to supplement working capital.

Aike Medical’s main products have been on the market since December 2022. The company’s operating revenue for 2022 to 2024 and the first nine months of 2025 is projected to be 900,900 yuan, 97.9874 million yuan, 199.9 million yuan, and 188 million yuan respectively; the net profit attributable to the parent company’s shareholders is expected to be -103 million yuan, -363 million yuan, 16.9695 million yuan, and 36.3889 million yuan respectively.

The actual controllers of Aike Medical are Lu Shuxian and Lu Yiran, who are father and son. Before the IPO, Lu Shuxian controlled 32.96% of the company’s shares by serving as the executive partner of Shanghai Aixiang, while Lu Yiran directly held 4.64% of the company’s shares, controlled an additional 4.60% of the shares by serving as the executive partner of Beijing Aichi, and controlled 2.20% of the shares by serving as the executive partner of Shanghai Yuanji. Therefore, Lu Shuxian and Lu Yiran collectively control 44.40% of the voting rights through direct shareholding and control of Shanghai Aixiang, Beijing Aichi, and Shanghai Yuanji.

Currently, Lu Shuxian serves as the chairman of the company, Lu Yiran serves as the general manager and director, Guo Ruijiu serves as the deputy general manager and employee representative director, and Ding Lin serves as the board secretary and financial head.

In terms of compensation, the total remuneration for Aike Medical’s directors, supervisors before the cancellation of the supervisory board, senior management personnel, and core technical staff for the years 2022 to 2024 and the first nine months of 2025 is expected to be 16.0071 million yuan, 12.6597 million yuan, 13.5085 million yuan, and 9.9032 million yuan respectively.

According to Rui Finance, Aike Medical’s secretary of the board and financial head Ding Lin is a post-75er with extensive experience in the financial field.

Ding Lin, born in 1978, is a Chinese national and a permanent resident of Hong Kong. He obtained his bachelor’s degree from the Diplomatic Academy and a master’s degree from HEC Paris. From 2007 to 2016, he served as vice president and director of Greater China in the investment banking division at BNP Paribas Securities (Asia) Limited, and as head of natural resources for Greater China at Citigroup Global Markets Asia Limited; from 2016 to 2021, he worked at Shanghai Fosun High Technology (Group) Co., Ltd. and Yidu Technology Co., Ltd.; from 2021 to 2022, he served as the company’s chief financial officer; and since 2022, he has served as the company’s board secretary and financial head.